A 2019 evaluation of opioid use disorder treatment resources in rural Utah counties

被引:1
|
作者
Ragsdale, Russell J. [3 ]
Nickman, Nancy A. [1 ,2 ]
Slager, Stacey [4 ]
Fox, Erin R. [5 ,6 ]
机构
[1] Univ Utah, Pharmacotherapy, 30 S 2000 E,Rm 4930, Salt Lake City, UT 84112 USA
[2] Univ Utah Hlth, Pharm Serv, 50 North Med Dr, Salt Lake City, UT 84132 USA
[3] Univ Utah Hlth Midvalley Specialty Pharm, Ambulatory Pharm Serv, Murray, UT USA
[4] Univ Utah, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT 84112 USA
[5] Univ Utah Hlth, Drug Informat & Support Serv, Salt Lake City, UT USA
[6] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA
关键词
INVOLVED OVERDOSE DEATHS; UNITED-STATES; NONMEDICAL USERS; BUPRENORPHINE; ACCESS; DRUG;
D O I
10.1016/j.japh.2021.03.019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: The opioid crisis significantly affects residents of rural communities who already experience poor health outcomes based on social determinants. Therefore, this project evaluated the reported availability and accessibility of opioid use disorder (OUD) treatment resources in rural Utah county pharmacies through a multistep process intended to estimate the distance (miles) to registered (waivered) OUD care providers and community pharmacies and, thus, the ability to fill prescriptions for OUD treatment medications. Methods: First, the United States Department of Agriculture Economic Research Service dichotomous classification scheme was used to identify nonmetropolitan counties. Second, online resources were used to identify the volume of waivered treatment providers and community pharmacies by county. Third, the driving distances to both resources were estimated according to ZIP Code and county. Finally, the immediate availability of filling a prescription for OUD treatment medications was determined by surveying community pharmacists in rural Utah counties. Results: Nineteen of the 29 Utah counties were identified as rural and included in the study. Pharmacists in 50 of the 75 viable pharmacies completed surveys (66.7% usable response rate). OUD treatment medications were immediately available for dispensing in 90% (45 of 50) of the responding pharmacies. Two of the 19 counties (10.5%) lacked a pharmacy, and 6 of the 19 counties (31.6%) lacked a registered OUD treatment provider. Driving distances ranged from 1 mile to 71 miles to the nearest pharmacy and from 1 mile to 96 miles to the nearest waivered treatment provider. Conclusion: OUD treatment medications were readily available in some but not all rural Utah pharmacies. However, geographic barriers may prevent reasonable access to treatment providers and pharmacies for residents of smaller, remote communities. (C) 2021 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:513 / 521
页数:9
相关论文
共 50 条
  • [31] Opioid Use Disorder: Diagnosis and Updated Treatment Options
    Li, Benjamin T.
    Riordan, Nina
    Banu, Sophia
    Murtaza, Syed
    Shah, Asim A.
    PSYCHIATRIC ANNALS, 2018, 48 (08) : 366 - 371
  • [32] Treatment of Prescription Opioid Use Disorder in Pregnant Women
    Guille, Constance
    Barth, Kelly S.
    Mateus, Julio
    McCauley, Jenna L.
    Brady, Kathleen T.
    AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (03): : 208 - 214
  • [33] An Exploratory Study of Sex and Gender Differences in Demographic, Psychosocial, Clinical, and Substance Use Treatment Characteristics of Patients in Outpatient Opioid Use Disorder Treatment With Buprenorphine
    Parlier-Ahmad, Anna Beth
    Martin, Caitlin E.
    Radic, Maja
    Svikis, Dace S.
    TRANSLATIONAL ISSUES IN PSYCHOLOGICAL SCIENCE, 2021, 7 (02) : 141 - 153
  • [34] Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder
    Gryczynski, Jan
    Nichols, Helen
    Schwartz, Robert P.
    Mitchell, Shannon Gwin
    Hill, Paulette
    Wireman, Kim
    DRUG AND ALCOHOL DEPENDENCE, 2019, 204
  • [35] Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice
    Deyo-Svendsen, Mark
    Cabrera Svendsen, Matthew
    Walker, James
    Hodges, Andrea
    Oldfather, Rachel
    Mansukhani, Meghna P.
    JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2020, 11
  • [36] Medication Treatment of Opioid Use Disorder
    Bell, James
    Strang, John
    BIOLOGICAL PSYCHIATRY, 2020, 87 (01) : 82 - 88
  • [37] Pharmacogenetics of Opioid Use Disorder Treatment
    Crist, Richard C.
    Clarke, Toni-Kim
    Berrettini, Wade H.
    CNS DRUGS, 2018, 32 (04) : 305 - 320
  • [38] Treatment of Perinatal Opioid Use Disorder
    Boyars, Lisa
    Guille, Constance
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2018, 45 (03) : 511 - +
  • [39] Treatment of Opioid Use Disorder in the Elderly
    LaGrotta C.
    Current Treatment Options in Psychiatry, 2020, 7 (4) : 531 - 543
  • [40] Trends in buprenorphine dosage and days supplied for new treatment episodes for opioid use disorder, 2010-2019
    Tilhou, Alyssa Shell
    Murray, Eleanor
    Wang, Jiayi
    Linas, Benjamin P.
    White, Laura
    Samet, Jeffrey H.
    Larochelle, Marc
    DRUG AND ALCOHOL DEPENDENCE, 2023, 252